A new research document was published in volume 16 of Tumult On July 25, 2025, entitled “Analyzing the functional differences and clinical characteristics of the R-Spondin family members in metastatic prostate cancer”.
In this study, researchers led by the first writer Aiden Deacon and the corresponding author Justin Hwang from the cities of the University of Minnesota-Twin investigated a group of genes known as a R-Spondin family (RSPO1/2/3/4) in advanced prostate cancer (PC). The RSPO gene family regulates WNT signaling, a path involved in the development of cancer.
Prostate cancer is the most common cancer among men in the United States and becomes particularly dangerous when spreading beyond the prostate. Most patients are treated with hormonal treatments aimed at the androgen receptor. However, many tumors eventually become durable.
The research team analyzed thousands of volume samples and found that RSPO2 changes were more common than changes in other R-Spondin genes or even some known cancer-related genes such as Ctnnb1 and APC. RSPO2 reinforcement appeared in over 20% of metastatic prostate cancer. Patients with these lesions have shown signs of more aggressive disease, including higher rates of mutation and greater tumor complexity.
Using laboratory models, the group discovered that RSPO2 increases the growth of cancer cells and causes a biological process called epithelial mesenchymal transition (EMT). EMT is known to promote the spread of volume and resistance to standard treatments. Unlike other genes on the same path, the RSPO2 also appeared to reduce the activity of the androgen receptor genes, suggesting that it drives a type of prostate cancer that is no longer based on hormones for growth.
“In the cell series, the RSPO2 over-expression caused an upward regulation of EMT streets, including EMT-Regulatory transcripts ZEB1, ZEB2 and TWIST1. ”
It is important that RSPO2 has shown structural differences from other R-spondin proteins, which may allow researchers to design drugs that specifically prevent their activity. Current treatments aimed at WNT Street are limited and there are no approved drugs to inhibit RSPO2. However, this study highlights RSPO2 as a promising therapeutic objective, especially for patients who do not respond to hormone -based treatments.
This research adds critical knowledge about how much aggressive prostate cancers develop and persist despite treatment. Identification of RSPO2 as a basic development of the disease opens new potential for treatment strategies aimed at improving the results for patients with advanced prostate cancer.
Source:
Magazine report:
Deacon, A., et al. (2025). Analyzing the functional differences and clinical characteristics of the members of the R-Spondin family in metastatic prostate cancer. Tumult. Doi.org/10.18632/oncotarget.28758.
